ASP Isotopes Inc.

ASP Isotopes (NASDAQ: ASPI) is a materials/isotope-enrichment company organized into three operating segments: (i) specialist isotopes and related services (Carbon-14, Silicon-28, Ytterbium-176, Molybdenum-100, plus the PET Labs / NuMed / ECNP radiopharmacy operations); (ii) nuclear fuels (HALEU/LEU uranium enrichment and Lithium-6, run through subsidiary Quantum Leap Energy LLC / "QLE"); and (iii) helium and LNG (Renergen, acquired January 2026). The core technology claim is two proprietary enrichment methods — Aerodynamic Separation Process ("ASP technology") and laser-based Quantum Enrichment ("QE technology") — applied to high-value, low-volume isotopes.

FY2025 revenue $23.849M (10-K companyfacts). Q2 2026: revenue $5.123M, gross profit $1.480M (28.9% GM), R&D $6.824M, SG&A $28.851M, operating loss -$34.195M (10-Q). H1 2026 net loss -$41.114M (10-Q cash-flow stmt). Cash $219.6M + ST investments $35.3M; convertible notes payable (fair value) $203.4M; total debt $59.8M; accumulated deficit -$272.8M; total equity attributable to ASPI $264.7M (10-Q balance sheet). The critical disclosure: "We have not generated any revenue from the sale of our enriched isotopes as of June 30, 2026" — all revenue is radiopharmacy doses (PET/SPECT) plus helium/LNG, not the core enrichment technology.

• monetization model: One-time product sales of enriched isotopes and radiopharmaceuticals; future long-term supply/offtake contracts for HALEU/medical isotopes; no SaaS/subscription (ASPI FY2023 10-K Item 1, sec.gov ; accession UNKNOWN).
• revenue mix: Q3 2024: ~100% radiopharmaceuticals (PET Labs); enriched isotope sales not yet material. FY2023: no revenue. Segment-note % share: UNKNOWN (single segment; disaggregation not in accessible filing) (Q3 2024 10-Q, same EDGAR CIK; accession UNKNOWN).
• who pays: Radiopharmaceutical manufacturers/hospitals; nuclear utilities; government program buyers (DOE/NNSA); research institutions (FY2023 10-K Item 1; Q3 2024 10-Q).
• margin_value_capture: Q3 2024 gross margin ~5%; operating margin negative. Value accrues to proprietary ASP enrichment tech and scarce isotope supply (Q3 2024 10-Q).

• customer classes: US Nuclear Utilities, Government - Program Buyers, radiopharmaceutical manufacturers, medical isotope distributors, research institutions.

Sources: SEC EDGAR CIK 0001920406; FY2023 10-K and Q3 2024 10-Q; accession numbers UNKNOWN (not verifiable offline).

ASP Isotopes Inc. is an isotope enrichment company. Its public disclosures, including the SEC EDGAR filing index for ASPI, indicate that it is commercializing a proprietary aerodynamic separation process for producing enriched isotopes.

The most authoritative filing for the business description is the company’s latest Form 10-K, located via the SEC EDGAR company filing index for CIK 0001922848:

• Primary source: SEC EDGAR ASPI 10-K index

URL: sec.gov

Accessed 2026-04-07.

Exact accession numbers are not captured in this environment; the index must be opened to retrieve the latest filing.

The company also maintains a website describing its technology and product focus:

• Company technology/product page: aspisotopes.com

Accessed 2026-04-07.

This is Tier 2 context, not a substitute for the 10-K.

No reliable segment-level revenue mix can be stated from the accessible filing index. ASPI is an early-stage isotope company and may not report multiple reportable segments.

The revenue mix by segment is: needs primary source validation.

To determine the true revenue mix, the analyst must retrieve the latest 10-K and, if applicable, the latest 10-Q, and inspect:

1. The income statement revenue line.
2. The revenue recognition footnote.
3. The segment reporting footnote, if any.
4. The MD&A discussion of revenue drivers.

If the latest 10-K states that the company operates in one segment or has no reportable segments, that is itself the segment-level answer. If it disaggregates revenue by product or by geography, that disaggregation must be used. Do not rely on a third-party summary.

The monetization model appears to be product-sale based: the company seeks to sell enriched isotopes to buyers in specialized industrial, medical, and semiconductor/quantum applications.

Potential revenue mechanisms visible from company disclosures and standard industrial practice include:

• Sale of enriched isotope material.
• Supply agreements or off-take contracts.
• Development or qualification batches.

However, the exact revenue recognition policy and whether the company recognizes revenue at a point in time or over time is a matter to be verified from the latest 10-K revenue footnote. That specific policy is needs primary source validation.

Source-bound claim: The company is not a software/subscription business; it is a physical-material producer. This is supported only by the company’s stated business description [SINGLE-SOURCE] until the 10-K Business section is opened and quoted.

Gross margin and operating margin cannot be verified from the accessible EDGAR filing index.

The reported gross margin is: needs primary source validation.

The reported operating margin is: needs primary source validation.

Early-stage enrichment companies often have negative or non-meaningful gross margins because initial revenue, if any, may not cover fixed production overhead. That inference is common sense, not a primary-source financial result. No specific margin should be carried into a model until it is extracted from the latest 10-K/10-Q.

Because the actual price per kilogram and actual cost structure are not currently disclosed in a verified form accessible to me, the unit-economics exercise below is explicitly illustrative. It shows the correct analytical formula and sensitivity framework. The inputs must be replaced with primary filing data before use.

Worked calculation appears in the “Worked calculation” section below.

The likely paying customers are institutional and industrial buyers:

• Radiopharmaceutical manufacturers or suppliers that need enriched isotope targets.
• Semiconductor materials firms or quantum-computing device makers that need enriched silicon.
• Research, nuclear, or industrial isotope users.

This customer-class description is supported by the company’s product descriptions on its website [Tier 2], but it is not yet confirmed by a named-customer exhibit in the accessible EDGAR index.

No named customers are identified in the accessible EDGAR filing index.

Any name appearing only in a press release or news article is single-source and must be tagged [SINGLE-SOURCE]. For a customer to become a load-bearing claim, it should appear in an SEC exhibit, such as a material agreement exhibit, a 10-K customer-concentration disclosure, or a subsequent event disclosure.

Customer-concentration percentages, if any, are: needs primary source validation.

The customer classes most consistent with ASPI’s stated product focus are:

1. Medical isotope / radiopharmaceutical buyers: entities that need enriched molybdenum-100, ytterbium-176, or similar materials for isotope production.
2. Semiconductor and quantum-computing material buyers: entities seeking enriched silicon-28 for next-generation devices or qubit-related materials.
3. Industrial/scientific isotope buyers: research institutions or industrial users needing specialty isotopes such as carbon-14 or chlorine-37.

Source: aspisotopes.com ; accessed 2026-04-07; Tier 2 corporate source.

Buyer archetypes are derived, not named in SEC filings:

• Radiopharmaceutical supply-chain executive: cares about purity, regulatory documentation, delivery reliability, and price.
• Semiconductor materials engineer: cares about isotopic purity, contamination, and reproducibility.
• R&D procurement officer: cares about sample availability, analytical traceability, and vendor qualification.

No specific named customer should be treated as real based on this note.

None identified. Any “top customers named from filings only” would need to come from SEC exhibits. Until then, the correct finding is: no named customers located in the accessible EDGAR index.

ASP Isotopes Inc. (“ASPI”) is a development-stage advanced materials company focused on isotope enrichment. Its stated technology is the Aerodynamic Separation Process, which it presents as a proprietary method for enriching isotopes for nuclear medicine, quantum computing, semiconductor, and other applications. Source: ASP Isotopes corporate/technology page, aspisotopes.com , accessed 2026-04-28.

Because ASPI is development-stage, its business model is not mature. The revenue model likely consists of eventual product sales of enriched isotopes, possibly long-term supply agreements, toll enrichment, or development contracts. However, the exact revenue structure must be confirmed against the ASPI 10-K and material contracts filed with the SEC. Source: SEC EDGAR ASPI filing index, sec.gov , accessed 2026-04-28.

Revenue mix by segment: needs primary source validation.

I cannot compute a reliable revenue mix without the filed 10-K or 10-Q segments. If ASPI has no significant product revenue, segment mix is not meaningful. If it reports contract research, development revenue, or initial isotope sales, the segment split must be pulled directly from the filing. Do not substitute an analyst estimate or a press summary for the primary filing.

The monetization model likely includes:

• Direct sale of enriched isotopes to end users or intermediaries.
• Long-term offtake or supply agreements with customers in nuclear medicine, semiconductor/quantum computing, and research.
• Possible development or toll enrichment arrangements.

This is a qualitative description only. The actual monetization model must be verified from the ASPI 10-K business section and from any material definitive agreements filed as exhibits to 8-Ks. Source: SEC EDGAR ASPI filing index, sec.gov , accessed 2026-04-28.

Gross margin: needs primary source validation.

Operating margin: needs primary source validation.

For a development-stage company, gross margin may be undefined or negative if reported. Do not assume scaled-margin economics for an enrichment business. Pull the latest 10-K and 10-Q income statements, then compute:

• Gross margin = (Revenue − Cost of revenue) / Revenue
• Operating margin = Operating income / Revenue

No verified input values are available here, so no calculation is performed from actual ASPI data.

The likely paying entities are:

• Nuclear medicine/pharmaceutical companies needing enriched isotopes.
• Semiconductor/quantum computing manufacturers needing isotopically pure silicon or other materials.
• National laboratories, research institutions, and government-related buyers.

This is an archetype-level description. Actual paying customers must be named only from the ASPI 10-K or from filed customer contracts. The current available primary-source set does not let me name a customer.

Top customers: needs primary source validation.

No customer names are supplied because I could not open the primary filings. The 10-K should be checked for customer concentration disclosures, and any named customer in an 8-K exhibit must be included before it is used. Do not infer a top customer from a press release or a speculative article.

Based on the company’s public positioning, the customer classes are:

• Radiopharmaceutical and nuclear medicine companies.
• Semiconductor and quantum computing manufacturers.
• Government/national laboratory buyers.
• Academic/research institutions.

These are archetypes, not verified customer names. Source: ASP Isotopes corporate/technology page, aspisotopes.com , accessed 2026-04-28.

The likely buyer archetypes are:

• Procurement/supply-chain managers at isotope users who require certified purity and reliable supply.
• R&D leaders at semiconductor or quantum computing firms evaluating isotopically purified materials.
• Regulatory/compliance teams at radiopharmaceutical firms that require validated production processes.
• Government program managers funding domestic isotope production capacity.

The actual buyer set must be identified from the 10-K revenue concentration disclosures and from filed contracts. No buyer name is asserted here.

No customer names are supplied because the primary filings were not openable in this environment. The instruction is explicit: never invent a customer. The correct source location is:

• ASPI 10-K, Customer/Revenue Concentration section.
• ASPI 8-K exhibits for material definitive agreements.
• Competitor filings may also disclose shared or adjacent customers.

Until those are pulled, treat ASPI’s customer base as unverified.

ASP Isotopes Inc. is a development-stage isotope-enrichment company. Its intended monetization model is to produce and sell enriched isotopes using a gas-phase aerodynamic separation process. The company’s EDGAR presence and disclosures describe a business that is still transitioning from technology development toward commercial production; it is not a mature revenue-generating industrial company.

needs primary source validation.

No verified segment-level revenue mix is reported in this memo because the relevant 10-K/10-Q segment note and revenue-recognition disclosure were not retrieved. To populate this correctly, pull the latest 10-K and the most recent 10-Q from the SEC EDGAR index and read:

• the segment-reporting note, if any;
• the revenue-recognition policy;
• the “Results of Operations” / MD&A section; and
• any customer-concentration note.

For a development-stage company, the observable revenue mix is often zero or near-zero product revenue, with possible engineering/feasibility revenue or pilot isotope sales. That is a hypothesis to verify, not a fact asserted here.

The expected monetization model, subject to primary-source validation, includes:

1. Sale of enriched isotopes — specialty enriched materials sold to nuclear, medical, and electronics/quantum-industry buyers.
2. Possible long-term off-take or supply agreements — contracts that may include prepayments or milestone payments.
3. Possible toll-enrichment or contract-manufacturing arrangements — enriching customer-supplied feedstock for a fee.
4. Potential licensing/engineering fees — if the company licenses its separation technology or provides engineering support.

These are the categories to verify against the 10-K “Business” section and revenue-recognition note. The exact monetization structure may be less developed than investor materials imply.

needs primary source validation.

Gross margin is likely negative or not meaningful in the current development stage because fixed production costs are not yet absorbed by volume. Operating margin is likely deeply negative because R&D and G&A dominate. The specific reported values must be read directly from the income statement in the latest 10-K/10-Q. Do not use a data-aggregator number as a substitute.

Potential paying counterparties include:

• advanced-reactor developers and nuclear fuel fabricators;
• isotope distributors and radiopharmaceutical supply-chain participants;
• semiconductor and quantum-computing material buyers; and
• government or national-laboratory programs.

These are buyer categories, not verified named customers. See “Who they sell to” below.

None verifiable in this session.

No customer names are asserted here. The 10-K customer-concentration disclosure and the “Major Customers” note must be checked. If management names customers in earnings calls or press releases, that is not equivalent to a filing-level disclosure.

Because ASPI is development-stage, unit economics are more important than current margins. The illustrative calculation in this memo uses enriched silicon-28 as a case study. The key economic insight is that the value is concentrated in the price premium for high-purity enriched product, not in the feedstock cost. However, the actual price premium and processing cost must be validated from company filings or customer contracts.

The plausible customer classes, based on company descriptions, are:

1. Advanced nuclear fuel developers — entities developing reactors that require HALEU or other enriched fuel.
2. Nuclear fuel fabricators — companies that assemble fuel assemblies for utilities or advanced reactors.
3. Isotope distributors — intermediaries that sell enriched stable or radioactive isotopes to research and medical users.
4. Semiconductor/quantum-materials buyers — companies or research institutions requiring enriched Si-28.
5. Radiopharmaceutical manufacturers — companies that use enriched targets to produce medical isotopes.

The likely decision-makers are:

• chief technology officers or technical supply-chain leaders at advanced-reactor companies;
• nuclear fuel procurement managers;
• specialty-gas and isotope supply-chain managers;
• R&D or manufacturing leaders at semiconductor/quantum-device companies; and
• government-program managers or national-laboratory procurement officers.

These are archetypes, not verified buyer names.

None verifiable in this session.

The instruction to name top customers only from filings requires pulling the latest 10-K. If the company has no material revenue, there may be no 10% customers. If there are material customers, they should appear in the concentration note. Do not substitute management commentary or press-release names for filing-level evidence.

ASPI’s segment mix has not been verified in this session. The company likely reports as a single operating segment because it is development-stage or early-commercial. However, even if it reports a single segment, investors should break down the business by isotope product line, because unit economics differ sharply across Carbon-14, Silicon-28, Molybdenum-100, Zinc-68, Ytterbium-176, Lithium-7, and other isotopes.

The likely customer classes, based on industry structure, are:

• Radiopharmaceutical manufacturers: companies producing Mo-99/Tc-99m generators.
• Semiconductor materials suppliers: companies producing isotopically enriched silicon wafers or silane.
• Quantum computing companies and research institutions: buyers of Silicon-28 for qubit experiments.
• Nuclear fuel fabricators and reactor vendors: buyers of Lithium-7.
• Pharma and industrial tracer users: buyers of Carbon-14 and other isotopes.

ASP Isotopes Inc. is an advanced materials company focused on isotope enrichment. The company’s stated positioning centers on a proprietary aerodynamic separation process, or ASP, which it claims can enrich isotopes for medical, semiconductor, quantum-computing, and potentially nuclear-fuel applications. This is a company-level description and should be revalidated against the latest 10-K.

The monetization model is best described as:

1. Isotope product sales — selling enriched isotopes by weight or batch to industrial, medical, or governmental buyers.
2. Long-term supply agreements — securing customers before production capacity is fully online.
3. Potential toll or contract enrichment — enriching customer-owned feedstock for a fee.

None of these revenue streams should be considered verified until the latest 10-K or 10-Q explicitly discloses a customer contract, backlog, or revenue recognition policy.

Likely customer classes, based on company disclosures:

• Radiopharmaceutical manufacturers and nuclear-medicine supply-chain participants.
• Semiconductor wafer or quantum-computing hardware manufacturers needing enriched silicon-28.
• Government laboratories or nuclear agencies.
• Nuclear-fuel fabricators if the company pursues uranium-related isotopes.

These classes are not verified buyer lists; they are logical segments based on the company’s stated product focus.

Buyers are likely technical procurement teams with long qualification timelines, regulatory constraints, and supply-security concerns. For medical isotopes, buyers require regulatory approval of source material. For semiconductor isotopes, buyers require high purity and repeatable production.

No named customers are cited here because no customer names have been verified against a primary SEC filing in this session. Any customer name appearing in secondary coverage should be treated as needs primary source validation unless confirmed directly in a 10-K, 10-Q, 8-K, or S-1 exhibit.

ASP Isotopes Inc.

ASP Isotopes describes itself as an advanced materials company that is developing isotope enrichment capability using a proprietary aerodynamic separation process. The company is not yet a scaled commercial producer. In its SEC filings, it historically presents itself as a development-stage/pre-revenue or early-revenue company; the most recent verified annual filing available to me is the Form 10-K for fiscal year ended December 31, 2023, accessed via the SEC EDGAR company search page for ASP Isotopes Inc. (https://www.sec.gov/cgi-bin/browse-edgar?company=ASP+Isotopes&owner=exclude&action=getcompany, accessed 2026-05-07). The exact accession number for that 10-K is pending validation; I refuse to invent the numeric accession string.

The company’s revenue model is not yet observable from a diversified reported segment basis. In the FY2023 10-K as identified, ASPI did not report a meaningful revenue mix broken into operating segments. The company has not disclosed a diversified segment table of the type seen in mature public companies. Therefore:

• Revenue mix by segment, as of FY2023: Not meaningful; no verified segment revenue disclosure.
• Historical revenue: needs primary source validation for exact zero-versus-nonzero treatment. My working assumption is that ASPI was pre-revenue or immaterial-revenue for FY2023.
• Gross margin: Not meaningful because there is no verified cost-of-goods-sold base against material product revenue.
• Operating margin: Deeply negative on a reported basis because the company has carried R&D, G&A, and share-based compensation expenses without offsetting revenue. Exact operating loss is needs primary source validation.

The business is designed to generate revenue primarily from the sale of enriched isotopes or from isotope enrichment services. Based on the company’s SEC registration statements and periodic filings, the monetization logic is:

1. Build or install an isotope enrichment line using Aerodynamic Separation Process technology.
2. Produce enriched isotopes to customer specification.
3. Sell the enriched isotope product under purchase orders or potential long-term supply agreements.
4. In some cases, customers may supply feed material or require qualification batches before commercial revenue.

The company has also signaled interest in nuclear fuel isotopes. However, any claim that ASPI is a current or near-term supplier of HALEU or enriched uranium is not supported by a license in the filings I identified. This is a major competitive contradiction discussed below.

From the company’s filings and disclosure language, the target customer classes are:

1. Nuclear medicine and radiopharmaceutical companies — potential buyers of enriched Carbon-14 or Molybdenum-100.
2. Semiconductor and quantum technology companies — potential buyers of isotopically pure Silicon-28.
3. Advanced nuclear fuel fabricators or reactor developers — potential buyers of enriched uranium/HALEU, but this is not yet established by license or production.
4. Research institutions and government programs — possible development partners or grant counterparties.

The buyer archetypes are business-to-business, specification-driven purchasers. They tend to care about:

• isotope purity,
• chemical form,
• delivery reliability,
• regulatory documentation,
• security of supply,
• price per gram or kilogram.

These buyers do not behave like commodity purchasers of generic materials. They require qualification batches and may sign long-term offtake agreements only after technical acceptance.

I cannot name a customer from the primary filings I have been able to retrieve. Any customer names in press releases were not independently verified in the SEC filing text. I therefore mark customer identity as needs primary source validation. Do not rely on unnamed-customer language as strong evidence of revenue quality.

FY2025 revenue $23.849M; Q2 2026 revenue $5.123M (H1 2026 $9.303M). Gross margin 28.9% (Q2 2026). The business is deeply loss-making: H1 2026 operating loss -$59.084M, net loss -$41.114M. Cash and cash equivalents $219.6M plus short-term investments $35.3M (= $254.9M total liquidity) as of June 30, 2026.

Isotope enrichment is a physical, qualification-gated bottleneck at the base of the physical-AI stack: Silicon-28 (for silicon-spin quantum computing and advanced semiconductors), HALEU (the fuel for the advanced reactors / SMRs that hyperscalers are contracting to power AI data centers), and Molybdenum-100 (cyclotron-produced medical imaging). ASPI's claim is that its aerodynamic + laser enrichment methods undercut the incumbent gas-centrifuge cost curve — and that it is the only commercial supplier of ultra-high-purity Si-28.

1. Cash runway. H1 2026 operating cash flow was -$41.094M (~$6.85M/month). At that rate, $254.9M liquidity funds ~3.1 years of runway — but Q2 2026 operating loss alone was -$34.2M (annualizes to -$137M), so the burn is accelerating as R&D (Q2 2026 $6.82M, +675% YoY) and the Iceland/US plant buildout ramp. The real constraint is whether ASPI reaches enriched-isotope revenue before dilution/financing exhausts the equity.
2. Si-28 physics. Natural silicon is 92.2% Si-28, 4.7% Si-29, 3.1% Si-30. Si-29's I=1/2 nuclear spin causes decoherence in silicon-spin qubits, so quantum-grade material must be enriched past ~99.995% Si-28 — removing a same-mass-neighbor (Δm ≈ 3.5%) impurity at the extreme tail of a separation cascade. This is why only a handful of entities can produce it; ASPI positions itself as the sole commercial supplier.
3. HALEU supply-security premium. HALEU is 5–20% U-235 (vs <5% LEU); TerraPower's Natrium reactor uses ~19.75% HALEU. US HALEU supply is Russia-dominated (TENEX), so any domestic/ally alternative carries a strategic premium that is not yet priced into ASPI's current $4–5 share price.
4. Dilution cost of the moat. ASPI funded the buildout with convertible notes ($203.4M at fair value on the 10-Q balance sheet) and equity: shares outstanding grew from 111.7M (Dec 31, 2025) to 130.1M (June 30, 2026), a +16.7% dilution in six months, and the July 15 QLE-note exchange adds another ~23.2M shares (~17.8% of the pre-exchange count) — the "cost of the moat" is being paid in equity at a depressed price.

• Zero enriched-isotope revenue through Q2 2026 despite "commenced commercial production of enriched isotopes at both ASP facilities during the first half of 2025" — 10-Q.
• C-14, Si-28, and Yb-176 initial commercial shipments all targeted "second half of 2026" — 10-Q.
• TerraPower definitive agreements: term loan (conditions-based) for Pelindaba HALEU facility + 10-year all-output HALEU offtake — 10-Q Note 13.
• Necsa MOU (Nov 2024) + Pre-Implementation Services Contract siting QLE's enrichment facility at Pelindaba — 10-Q.
• July 15, 2026 QLE note exchange: $109.2M QLE convertible notes → ~23.2M ASPI shares (~17.8%), cutting QLE notes from $219.8M to $110.7M, to simplify QLE's capital structure ahead of a planned separate US listing — EX-99.1.
• Renergen (South Africa helium/LNG, acquired Jan 2026) and Skyline (Hong Kong construction, deconsolidated March 2026) show a serial roll-up pattern around the core enrichment story — 10-Q.

1. Si-28 throughput ceiling vs revenue. Mann (Emerging Growth Conf, 08-20): first 48 stages assembled, second 48 in assembly (~100-stage plant); ~80 kg/yr at 99.995% (raised from ">50 kg" prior, "~10 kg" original) once the full 48-stage plant + ~200 service compressors operate. Spot Si-28 (99.99%) is $10,000–$30,000/kg (NextBigFuture). → 80 kg/yr × $10–30K = $0.8M–$2.4M/yr at spot. Even at the ~$300K/kg production-cost figure (Benchchem, 99.99%), 80 kg = $24M/yr — still ≤20% of the ~-$118M annualized operating loss (H1 2026 -$59.08M). Si-28 is a strategic/qualification asset, not a near-term P&L driver.
2. Capacity share (scarcity leg). Global Si-28 capacity was 380 kg (2024, all purities); the market is $128M (2025) → $228M (2031), +10.1% CAGR (QYResearch). ASPI's 80 kg/yr at 99.995% ≈ 21% of global capacity at the top of the purity ladder — the scarcity is real, but it is a tiny denominator.
3. Cost of moat vs moat defended (helium cash engine). Renergen Phase 2: ~900 MMcf/day liquid helium + 34,000 GJ/day LNG → ~$370M rev / ~$300M gross profit at $600/Mcf He + $14/GJ LNG (Mann, 08-20). Phase 1: 2,500 GJ/day LNG + 250 kg/day LHe (425, 08-04). But this cash engine is being spun into ENDRA (reverse merger; ASPI keeps ~89% pre-private-placement, 425, 08-04) — the parent monetizes the cash generator while retaining the unproven isotope ramp.
4. HALEU demand denominator. QLE MOU with a large publicly-traded U.S. nuclear utility (8-K, 03-06-2026); projected HALEU demand $37B through 2037, 50 MT/yr by 2035, 500 MT/yr by 2050 (StockTitan/Fermi America context). TerraPower offtake ~15 t/yr from 2028 ≈ ~30% of the 2035 demand bucket if U-235 enrichment is approved — which it is not (8-K 08-18: "has not applied... to U-235, nor received permission... to test").

1. Helium/LNG revenue at nameplate. Phase 1 = 70 MCF/day He + 2,500 GJ/day LNG; Phase 2 = 13× Phase 1 = 900 MCF/day He + 34,000 GJ/day LNG (8-K EX-99.1, helium offtake). At the contracted >$600/MCF He and >$16/GJ LNG (5-yr take-or-pay, Asian industrial-gas co; SA food-processor LNG): Phase 1 ≈ 70×$600 + 2,500×$16 = $42K+$40K = ~$30M/yr; Phase 2 ≈ 900×$600 + 34,000×$16 = $540K+$544K = ~$395M/yr. At 80%+ GM → Phase 2 gross profit ~$316M/yr ≈ the entire $300M/2031 target. The bridge is helium-dominated; Si-28 ($0.8–2.4M/yr at 80 kg) and radiopharmacy (~$20M/yr at 28.9% GM) are rounding error.
2. Timeline risk on the target. Phase 2 construction starts 2H 2026 with a ~44-month build → Phase 2 revenue ~2030, one year before the 2031 target. The $300M/2031 number therefore assumes Phase 2 is fully built, funded, and ramped on an aggressive schedule.
3. Funding is conditional, not committed. Phase 2 = up to $750M senior debt ($500M U.S. DFC + $250M Standard Bank), "subject to negotiation and definitive agreements" (BusinessDay 09-10); $40M DFC already received for Phase 1. Separately, a Standard Bank Second Amendment (ZAR230.5M ≈ $14.2M secured term loan) carries a Put Option Agreement: ASPI granted the lender the right, on a continuing event of default, to require ASPI to buy 1,546,268 pledged ASPI shares at 100% of the 5-day JSE VWAP — the parent has pledged its own equity against subsidiary debt.

Contribution margin per kg:

\[

\$5,000 - \$2,000 = \$3,000

\]

Breakeven volume:

\[

\$20,000,000 / \$3,000 = 6,667 \text{ kg/year}

\]

This means the illustrated model requires roughly 6.7 metric tons per year of enriched isotope sales at these assumed prices and costs just to cover fixed cash operating costs. For a specialty isotope product, that is a significant volume; if the real fixed cost is lower or the real price is higher, the breakeven volume changes materially.

This calculation shows that if ASPI’s real fixed costs are high and its realized isotope prices are in the low thousands of dollars per kilogram, it likely needs multiple tons per year of specialty isotope shipments to break even. Since specialty isotope markets can be small, this is a central risk.

The company’s actual fixed costs, price, and variable cost must be pulled from the latest 10-K/10-Q. Until they are, the actual economic result is needs primary source validation.

\[

\text{Break-even utilization} = \frac{\$8{,}000{,}000}{200 \times (\$100{,}000 - \$20{,}000)}

\]

\[

= \frac{\$8{,}000{,}000}{200 \times \$80{,}000}

= \frac{\$8{,}000{,}000}{\$16{,}000{,}000}

= 0.50

\]

So the illustrative break-even utilization is 50%.

The sensitivity shows that the economics are highly sensitive to price and variable cost. If ASPI’s actual price per gram is lower or its variable cost is higher, the required utilization can exceed 100%, meaning the product line would be structurally unprofitable under those assumptions.

\[

\text{Feed required} = \frac{1}{0.92223 \times 0.70} = 1.55 \text{ kg natural Si per kg enriched Si-28}

\]

\[

C_{\text{feed}} = 1.55 \times 3 = \$4.65/\text{kg}

\]

\[

\text{Gross profit per kg} = 20{,}000 - 4.65 - 5{,}000 = \$14{,}995.35/\text{kg}

\]

At 1,000 kg/year:

\[

\text{Annual gross profit} = 14{,}995.35 \times 1{,}000 = \$14{,}995{,}350

\]

Feedstock cost is nearly irrelevant under these assumptions. The economics depend overwhelmingly on realized enriched-isotope price and conversion cost. That means ASPI’s eventual viability would depend on:

1. achieving customer qualification and a price premium;
2. demonstrating low conversion cost at scale; and
3. maintaining sufficient throughput to absorb fixed costs.

These are exactly the points that cannot be verified from third-party summaries and must be checked against actual ASPI disclosures.

No row in this table should be treated as a verified fact.

Annual contribution = 100 kg × $100,000/kg × 60%

Annual contribution = $6,000,000

Payback = $50,000,000 ÷ $6,000,000

Payback ≈ 8.3 years

This sensitivity shows the thesis is highly sensitive to price, volume, and margin assumptions. Until actual filings provide capex, capacity, price, and cost data, this calculation cannot support a conviction score.